Niagen Bioscience (NAGE) investor relations material

Company overview and business model

• Operates as a global bioscience company focused on healthy aging, pioneering research on NAD+ and its role in cellular metabolism.

• Commercializes proprietary Niagen® (nicotinamide riboside chloride) as a dietary and pharmaceutical ingredient, with products available for both consumer and clinical use.

• Maintains a robust patent portfolio and collaborates with over 300 research institutions worldwide to advance NAD+ science.

• Supplies pharmaceutical-grade Niagen® to FDA-registered outsourcing facilities and compounding pharmacies for intravenous and injectable formulations.

• Products have received regulatory approvals in the US, Canada, EU, Australia, and other markets, and are supported by extensive clinical research.

Financial performance and metrics

• As of March 31, 2026, had 79,624,227 shares of common stock outstanding and a net tangible book value of $0.97 per share.

• After a $50 million offering at $3.45 per share, net tangible book value would rise to $1.33 per share, with immediate dilution of $2.12 per share to new investors.

• Outstanding options and restricted stock units could further dilute shareholders.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including working capital, capital expenditures, debt repayment, and administrative expenses.

• May allocate funds to acquisitions or investments in complementary businesses or products, though no current commitments exist.

• Pending use, proceeds will be invested in money market funds, government obligations, and similar instruments.